Low Risk of Birth Defects for Infants Whose Mothers Are Treated With Anti–Tumor Necrosis Factor Agents During Pregnancy

摘要: Background & Aims Safety data on anti-tumor necrosis factor (anti-TNF) treatment during pregnancy are limited. We studied the risk of birth defects after anti-TNF in early pregnancy. Methods collected 1,272,424 live-born infants identified from Danish (2004–2012) and Swedish (2006–2012) population-based health registers. determined prevalence among born to women with chronic inflammatory disease (inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic or psoriasis), (n = 683) without 21,549) pregnancy, general population. compared any major defect by organ system for treatment. Risks were presented as odds ratios (ORs) 95% confidence intervals (CIs). adjusted maternal age, parity, smoking, body mass index, multiple gestation, country, diagnosis. Results Birth more prevalent regardless status, than population (4.8% vs 4.2%). occurred 43 683 who received (6.3%), 1019 (4.7%). The OR receiving therapy was 1.32 (95% CI, 0.93–1.82); a cardiovascular 1.60 0.93–2.58), urinary 2.22 0.86–4.71). Conclusions Based an analysis registries Denmark Sweden, agents had slightly (but not significantly) higher having children defects. Although larger studies needed, heterogeneity observed did indicate common etiology.